Related by context. All words. (Click for frequent words.) 68 Oncotype 66 Oncotype DX Recurrence Score 65 PROLARIS 63 Cologuard 63 Oncotype DX colon cancer 62 GeneSightRx 62 gefitinib Iressa 62 miRview ™ squamous 61 HERmark assay 61 co receptor tropism 61 KRAS mutation 61 ChemoFx 61 MammaPrint 61 Roche AmpliChip 61 OnDose 61 Corus CAD 61 eTag assays 61 trastuzumab Herceptin 61 genetic biomarkers 61 EarlyCDT Lung 61 miRview TM squamous 61 DNA methylation biomarker 61 MammaPrint R 61 microRNA biomarkers 61 FullTerm 60 miRview TM mets 60 pharmacogenetic testing 60 Oncotype DX ® 60 NMP# 60 PLAC test 60 VeriStrat 60 DNA methylation markers 60 multivariate regression analysis 60 MiCK assay 60 BREVAGen 60 Mammostrat 60 VerifyNow 60 Tesmilifene 60 KRAS status 60 CT Colonography 60 FDG-PET/CT 59 OVA1 59 Oncotype DX 59 Recurrence Score 59 neratinib 59 MTWA testing 59 predictive biomarkers 59 Septin9 59 p# biomarker 59 HERmark 59 methylation markers 59 transrectal ultrasound guided 59 AttoSense 59 miRview meso 59 Septin 9 59 VKORC1 59 EUS FNA 59 PathFinderTG 59 LungAlert TM 59 UroVysion 59 #F FDG PET 59 Angiolix 59 BREVAGen ™ 59 nomograms 59 ImmuKnow 59 exemestane Aromasin 59 prognostic biomarker 58 miRview ™ mets 58 Zolinza 58 molecular biomarkers 58 preclinically 58 Xelox 58 gene amplification 58 LungExpress Dx 58 ErbB2 positive 58 genetic polymorphisms 58 Velcade bortezomib 58 Campath alemtuzumab 58 COR Analyzer 58 Pulmotype 58 differentiate squamous 58 Corgentin 58 Oncotype DX breast cancer 58 DCVax R 58 MAGE A3 ASCI 58 miRview squamous 58 Cervista HPV HR 58 HuMax 58 molecular subtypes 58 molecular biomarker 58 rEEG 58 Framingham Risk Score 58 thalidomide Thalomid 58 pertuzumab 58 Modrenal 58 immunochemical fecal occult 58 Pertuzumab 58 breast cancer metastasis 57 Aureon 57 ZOLINZA 57 Getzenberg 57 Immunohistochemistry 57 VerifyNow P#Y# 57 Prostate Px + 57 K RAS 57 Vectibix panitumumab 57 NPM1 57 DNA methylation biomarkers 57 ZACTIMA 57 PCA3 57 enzastaurin 57 genes CYP#C# 57 mammographic density 57 AdnaTest 57 xTAG RVP 57 pharmacogenetic test 57 stratifying patients 57 urine dipstick 57 Avise PG 57 Reynolds Risk Score 57 CIN2 + 57 tumor histology 57 ixabepilone 57 Hormone receptor 57 Cardiotoxicity 57 multigene expression test 57 TOP2A 57 pharmacogenetic tests 57 Squamous 57 CupPrint 57 FDG PET 57 ELISpot 57 NMP# assay 57 DNAwithPap TM Test 57 EGFR mutation status 57 deCODE AF TM 57 Trastuzumab Herceptin 57 CellSearch ™ 57 prognostic variables 57 OvaDx 57 ADAGIO study 57 Temsirolimus 57 anti CD# antibodies 57 murine models 57 PITX2 methylation 56 metabolomic profiling 56 trastuzumab Herceptin ® 56 HPV genotyping 56 PreGen Plus 56 vorinostat 56 prognostic indicators 56 cediranib 56 NCCN guidelines 56 genomic biomarkers 56 NMP# BladderChek 56 Neoadjuvant 56 tropism assay 56 ColoMarker 56 florbetaben 56 FASLODEX 56 nomogram 56 differentiated thyroid 56 miRview mets 56 radioimmunotherapy RIT 56 pain palliation 56 FDG PET imaging 56 HE4 56 vitro assay 56 CaPSURE 56 Outpatient Setting 56 molecular profiling 56 HER2 expression 56 transient elastography 56 Risk Stratification 56 PGxPredict 56 preoperative staging 56 Neuvenge 56 adjuvant therapies 56 Tarvacin 56 T#I [002] 56 Sentinel Lymph Node Biopsy 56 radiolabeled TM# 56 sDNA 56 Lp PLA 2 56 K ras mutations 56 Onconase 56 Belldegrun 56 CyPath ® 56 fluoropyrimidine 56 Amplimexon 56 molecular diagnostic assay 56 faecal occult blood 56 galiximab 56 HORIZONS AMI trial 56 Shark cartilage 56 fine needle aspiration 56 Onko Sure TM 56 antiangiogenic therapy 56 Human Leukocyte Antigen 56 chemoprevention trials 56 Clarient Insight Dx 56 predictive biomarker 56 BRACAnalysis ® 56 CellSearch System 56 PCA3 assay 56 QOPI 56 BreastCancer 56 ELISPOT 56 ToGA 56 HER2 overexpression 56 BladderChek 56 Sorafenib Nexavar 56 OnDose TM 56 SYNTAX trial 56 GeneSearch 56 enzyme immunoassay EIA 56 Azedra 56 HOXB# 55 stage IIIA 55 HER2 positive metastatic breast 55 immunosuppressive regimens 55 pharmacogenetic 55 UGT#A# 55 Diabetes Risk Score 55 PROCHYMAL 55 oral FTY# 55 warfarin dosing 55 prognostic marker 55 Lisofylline 55 multi analyte 55 Myocardial Perfusion Imaging 55 endometrial biopsy 55 Electronic Brachytherapy 55 KRAS gene mutations 55 antiangiogenic agent 55 sorafenib Nexavar 55 tumor subtypes 55 DCVax 55 KRAS mutations 55 urine cytology 55 fluorodeoxyglucose positron emission tomography 55 ImmuKnow R 55 ALTTO 55 IL#B 55 MGd 55 YONDELIS 55 Haptoglobin 55 AlloMap 55 sorafenib tablets 55 EBUS FNA 55 BRAF inhibitors 55 Fecal occult blood 55 Her2/neu 55 immunochemical 55 histological subtype 55 sargramostim 55 QuadraSphere 55 Logistic regression 55 JAK2 inhibitor 55 prognostic markers 55 IRESSA 55 skin sterol 55 WavSTAT 55 BEXXAR Therapeutic Regimen 55 Combidex 55 Seeplex 55 SLN biopsy 55 EGFR mutation 55 warfarin dosage 55 tumor biopsies 55 VERSANT 55 PREVU x 55 Degarelix 55 CINQUIL 55 Perforomist ™ Inhalation Solution 55 ClearPath HDR 55 FFR measurements 55 Genentech Herceptin 55 Multiple logistic regression 55 Resolute stent 55 taxane therapy 55 Xcellerated T Cells 55 CellPort Technologies 55 Prognostic Value 55 bioFILM PA ™ 55 nutrigenomic 55 BRAF V#E mutation 55 Cervista HPV 55 preclinical efficacy 55 microRNA expression 55 colonoscopy flexible sigmoidoscopy 55 AF Suppression 55 NSCLC tumors 55 Oncotype DX TM 55 LungSign TM 55 AZILECT ® 54 biomarker assay 54 DCE MRI 54 Subgroup analysis 54 teriflunomide 54 LY# [003] 54 BRAF inhibitor 54 OvaRex MAb 54 intra arterial chemotherapy 54 bevacizumab Avastin 54 Randomized trials 54 multiplex PCR 54 axillary dissection 54 antiplatelet therapies 54 genomewide 54 PhenoSense GT 54 miRview ® 54 Theranostics 54 qRT PCR 54 neoadjuvant treatment 54 Cytoxan ® 54 warfarin dose 54 ImmuKnow assay 54 hormone receptor negative 54 NuroPro ® 54 thyroglobulin 54 STRIDE PD 54 SELDI TOF MS 54 somo • v 54 K ras 54 F FDG PET 54 HLA DQ 54 tubulin inhibitor 54 deCODE ProstateCancer TM 54 microarray analysis 54 Dapagliflozin 54 TGFBR1 * 6A 54 GnRH agonists 54 mutational status 54 NMR LipoProfile test 54 tumor subtype 54 bortezomib Velcade 54 TLE3 54 ParAllele 54 AssureRx 54 diagnostic modality 54 estrogen receptor ER 54 sipuleucel T 54 PROGENSA PCA3 assay 54 biomarker 54 eprotirome 54 standard chemotherapy regimen 54 Celgene Revlimid 54 pancreatic lung 54 RNA seq 54 EFAPROXYN 54 RX ACCULINK 54 TLR9 agonists 54 Radient Pharmaceutical current 54 immunohistochemical analysis 54 pretreatment serum 54 serologic tests 54 Arranon 54 Flexible sigmoidoscopy 54 stratify patients 54 oral Xeloda 54 monoclonal antibody therapies 54 Trofile assay 54 HyACT 54 MTWA 54 prostate cancer PCa 54 univariate 54 GAMMAGARD 54 immunohistochemical 54 Immunotherapeutic 54 HemeScan test 54 NCCN Guidelines 54 ImmunoGen TAP technology 54 ChemoFx ® 54 Cristofanilli 54 gemcitabine Gemzar 54 Accelerated Partial Breast Irradiation 54 fluvastatin 54 adjuvant therapy 54 Epigenomics proprietary 54 balloon brachytherapy 54 Azacitidine 54 xCELLigence System 54 K ras gene 54 NADiA 54 Xanafide 54 immunohistochemical staining 54 kinase profiling 54 bioluminescent imaging 54 preoperative chemotherapy 54 percutaneous cryoablation 54 Lucanix 54 Velculescu 54 PTK# 54 diagnostic biomarker 54 Glycominds 54 Hybrid Capture 54 RECIST Response Evaluation Criteria 54 deCODE BreastCancer 54 aromatase inhibitors AIs 54 vemurafenib 54 subgroup analyzes 54 Digital Mammographic Imaging 54 miRNA assays 54 Rosetta Genomics microRNA 54 pediatric malignancies 54 debulking surgery 54 endocrine therapies 54 Ag Ab Combo 54 NMR LipoProfile 54 Aflibercept 54 pemetrexed Alimta 54 antiplatelet medications 54 antiangiogenic agents 54 Pharmacogenomic 54 molecularly targeted therapy 54 EGFR inhibition 54 Serum HER-2/neu Test 54 JAK inhibitors 54 mutational analysis 54 EGFR antibodies 54 Array CGH 53 #F FDG 53 diagnostic prognostic 53 PARP inhibition 53 Pemetrexed 53 delafloxacin 53 tumor hypoxia 53 Co Receptor Tropism 53 pharmacodynamic properties 53 Mepact 53 Cerashield 53 alvespimycin 53 CYP#D# genotype 53 Prognostic 53 genotypic resistance 53 Insegia 53 NuroPro PD 53 Alternans 53 biologic pathways 53 QuantiFERON TB Gold 53 hypoxic tumors 53 T SPOT.TB 53 BSGI MBI 53 prostatic adenocarcinoma 53 Pharmacogenetic 53 RX Acculink 53 Elvitegravir 53 PD2i ® 53 ER CHOP 53 Trofex 53 NEUVENGE 53 CTAP# Capsules 53 SIR Spheres 53 ResponseDX Colon TM 53 NPM1 mutation 53 PKCi 53 RT PCR assay 53 hormone receptor status 53 therapeutic regimens 53 Allovectin 7 ® 53 Flow cytometry 53 bevacizumab Avastin Genentech 53 chemosensitivity 53 AtherOx 53 malignant lesions 53 Microwave Ablation System 53 prognostically 53 BC SeraPro 53 metastatic gastric 53 oncologic outcomes 53 chemoembolization 53 DNA methylation patterns 53 colon capsule endoscopy 53 SERMs 53 conventional angiography 53 sentinel node biopsy 53 regorafenib 53 AGHD 53 Delcath PHP System 53 epithelial tumors 53 Saforis 53 proton MR spectroscopy 53 ticagrelor Brilinta 53 CyPath 53 varespladib 53 multivariate analyzes 53 PREVU x LT 53 postmenopausal hormone 53 Dendreon Provenge 53 Afib 53 Ceflatonin 53 MammaPrint ® 53 conditional logistic regression 53 platelet reactivity 53 KRAS mutation status 53 Vandetanib 53 breast cancer subtypes 53 Circulating Tumor Cells 53 Symadex 53 erlotinib Tarceva 53 bone density measurements 53 Warfarin Coumadin 53 RQ PCR 53 Mutation Analysis 53 FLT3 53 cellular immunotherapy 53 Biomerk Tumorgrafts 53 NADiA TM 53 Fractional Flow Reserve 53 ResponseDX 53 HIV tropism 53 TPMT 53 mertansine 53 flavopiridol 53 tropism testing 53 HE4 test 53 pharmacogenomic tests 53 diagnose Alzheimer disease 53 P2V TM 53 VeraTag 53 multivariate Cox 53 PROactive study 53 Ixempra 53 HER2 positive cancers 53 Factor VIIa 53 Crit Line 53 transvaginal sonography 53 patient subpopulations 53 SpHb 53 Optical Biopsy System 53 CCR5 receptor antagonist 53 BioVant 53 transcranial Doppler ultrasound 53 CoFactor 53 HIF PH inhibitors 53 metastatic neuroendocrine tumors 53 Poly ICLC 53 mSEPT9 53 AclarusDx 53 ABL1 53 APOE genotype 53 CLIA certified laboratories 53 Orazol 53 Saladax 53 HistoScanning 53 DEXA scan 53 Teysuno 53 aCGH 53 Digene HPV Test 53 microRNA profiling 53 PGx 53 pelvic ultrasound 53 BRCA2 mutation carriers 53 ColoMarker ™ 53 prostate cancer CaP 53 eribulin mesylate 53 inflammatory biomarkers 53 CT angiograms 53 Rasilamlo 53 putative biomarkers 53 Prostate Specific Antigen 53 AGTR1 53 paclitaxel Taxol 53 IGRAs 53 InSure 53 pretargeting 53 Caris MPI 53 RRM1 53 differential gene expression 53 cerebral oximetry 53 immunoblot 53 Hemoccult II 53 ImClone Erbitux 53 PIB PET 53 Amniocentesis 53 radionuclide therapy 53 recurrent metastatic 53 RT qPCR 53 serologic testing 53 neoadjuvant chemotherapy 53 lung pancreatic 53 Hemoglobin A1c 53 dosimetric 53 AspirinWorks 53 gene expression profiling 53 BioMAP 53 atrasentan 53 CareEngine System 53 HuMax HepC 53 IGFBP2 53 KIF6 gene variant 53 reslizumab 53 nonsmall cell lung cancer 53 XELOX 53 xanthine oxidase inhibitor 53 Medicsight ColonCAD 53 Bifantis 53 BioMAP ® Systems 53 anastrozole Arimidex 53 Epidermal Growth Factor Receptor 53 Vaxfectin TM 53 hormone therapy estrogen 53 Interferon beta 53 serum biomarkers 52 risk stratification 52 prognostic biomarkers 52 MammoSite RTS 52 LEUKINE 52 Axial Biotech 52 Fingolimod 52 Mammosite 52 OncoVex 52 RECAF TM 52 PCA3 test 52 epigenetic therapies 52 GSTP1 52 metaanalysis 52 node metastases 52 BRCA testing 52 Onko Sure ® 52 PREVU * 52 BCIRG 52 genotyping assay 52 radiologic imaging 52 Third Eye Retroscope 52 biomarker assays 52 mammographically 52 imatinib resistance 52 endoscopic ultrasound 52 ABCB1 52 Lp PLA2 52 intensive lipid lowering 52 aT cell 52 chemopreventive agents 52 Epidemiologic studies 52 STEP BD 52 AFRS TM 52 multimodality therapy 52 Cardica Microcutter XPRESS 52 lapatinib Tykerb 52 Deforolimus 52 HepDirect prodrug 52 Hedgehog inhibitor 52 leflunomide 52 pancreatic adenocarcinoma 52 LRP5 52 lipid abnormalities 52 B7 H3 52 Screening Trial 52 LungExpress Dx TM 52 CellSearch TM System 52 mutated K ras 52 Accuray CyberKnife 52 quantitative cytology 52 guaiac 52 DaTSCAN 52 Surgical resection 52 KineMarker TM 52 S. maltophilia 52 Meta analyzes 52 CCX# 52 hsCRP 52 virotherapy 52 Affymetrix arrays 52 MR spectroscopy 52 Prostate Cancer Progression 52 gene methylation 52 ReoPro 52 OVA1 ® 52 AviaraDx 52 antiplatelet drugs 52 CLIA laboratory 52 perfusion imaging 52 Sequencing Systems 52 nCounter 52 Vitro Diagnostic 52 Cellvizio R 52 biostatistical analysis 52 clinically localized prostate 52 dasatinib Sprycel 52 Interferon alfa 52 DNAwithPap Test 52 sputum specimens 52 Novartis Zometa 52 AZILECT R 52 IgM antibody 52 Poisson regression 52 Automated Breast Ultrasound 52 metastatic pancreatic 52 ColonSentry ™ 52 commercialize deforolimus 52 mTOR inhibitors 52 bevacizumab Avastin ® 52 anti CD3 52 logistic regression analyzes 52 MEVACOR 52 Allovectin 7 52 cetuximab Erbitux 52 virologic responses 52 catheter angiography 52 standard chemotherapy regimens 52 genomic biomarker 52 trastuzumab DM1 T DM1 52 Valopicitabine 52 deCODE BreastCancer TM 52 gastrointestinal malignancies 52 noninvasive diagnostic 52 small molecule activators 52 thromboembolic disease 52 DEEP AF 52 histone deacetylase inhibitor 52 ReN# 52 comparative genomic hybridization 52 Bucindolol 52 Breast Cancer Assay 52 intraperitoneal chemotherapy 52 Tarceva TM 52 elevated CRP 52 peptide antigens 52 NADiA ProsVue 52 somatostatin analogues 52 Quantitation 52 Renal Cell Carcinoma RCC 52 Subgroup analyzes 52 IDI MRSA 52 ependymomas 52 clinicopathologic 52 myocardial viability 52 aleglitazar 52 OvPlex 52 NSABP 52 cardiotoxic effects 52 endoscopic ultrasonography 52 BRAF mutation 52 surrogate endpoint 52 predictive algorithm 52 cranial radiation 52 ResponseDX Lung TM 52 PROSTVAC TM 52 Genetic variants 52 kinase inhibition 52 Genotypic 52 pharmacodynamic markers 52 abnormal cytology 52 Vizilite 52 clinico pathological 52 nCounter Analysis System 52 RPC Onko Sure 52 Spartan RX CYP#C# 52 angiographically 52 Genentech Tarceva 52 clevidipine 52 NCCN Clinical Practice Guidelines 52 vivo preclinical 52 BrachySil TM 52 hematological parameters 52 coagulation abnormalities 52 Galectin 3 52 SELDI TOF 52 antigen PSA 52 canakinumab 52 Evoltra 52 Squalamine 52 quantitative RT PCR 52 Fondaparinux 52 genomic alterations 52 GSK# [002] 52 angiogenesis inhibitor 52 invasive coronary angiography 52 microsatellite instability 52 Diovan HCT 52 Mantoux test 52 refractory metastatic 52 DSM IV diagnoses 52 CRH O'Regan System 52 Granulocyte Colony Stimulating Factor 52 novel peptide 52 idiotype vaccine 52 CYP#A# inhibitors 52 ACRIN 52 COLD PCR 52 Previstage TM GCC 52 bone scintigraphy 52 Metastatic colorectal cancer 52 Gilead Viread 52 chromium picolinate supplementation 52 cervical carcinoma 52 APTIMA HPV 52 Alferon N 52 radiotracers 52 PITX2 52 XmAb# 52 Fulvestrant 52 Multivariate logistic regression 52 Affymetrix microarray technology 52 localized prostate 52 TLR antagonists 52 KRAS variant 52 DLQI 52 conjoint analysis 52 CardioFit 52 T1c 52 coagulation assays 52 TransVax tm 52 SensiGene 52 prognostic significance 52 mediastinoscopy 52 Avastin bevacizumab 52 genomic profiling 52 Coronary angiography 52 calcineurin inhibitors 52 autologous cellular immunotherapy 52 mTOR kinase 52 HemeScan 52 PCR assay 52 TRUS 52 logistic regression models 52 xMAP Technology 52 FGFR2 gene 52 neoadjuvant 52 Randomized clinical trials 52 SPECT CT imaging 52 exome sequencing 52 Novo TTF 52 ENMD # 52 Hepatocellular Carcinoma HCC 52 Dasatinib 52 biomarkers 52 prognostic indicator 52 QPCR 52 Chronix 52 waist circumference WC 52 Fc gamma receptor 52 CYT# potent vascular disrupting 52 Liver biopsy 52 Biophysical# 52 definitively diagnose 52 NPRL2 52 noninvasive imaging 52 CVac 52 DFCI 52 CYP#C# [001] 51 molecular abnormalities 51 rxRNA ™ compounds 51 receptor tyrosine kinase inhibitor 51 EBUS 51 ADVEXIN therapy 51 colorectal cancer CRC 51 FDG PET scan 51 Genomic Grade 51 PEGylated interferon 51 HIV HCV coinfected 51 pharmacodynamic effects 51 MyVax R 51 Prostate Specific Antigen PSA 51 oral ridaforolimus 51 opto acoustic 51 HIV protease inhibitors 51 adjuvant radiation 51 prospectively defined 51 Prostate AdenoCarcinoma Treatment 51 relapsed SCLC 51 immunohistochemistry 51 Bevacizumab 51 susceptibility loci 51 Bionate ® PCU 51 Islet transplantation 51 histological subtypes 51 ChronVac C R 51 BACcel ™ 51 BRCA2 carriers 51 product ColonSentry TM 51 Biologics Compendium 51 Xinlay 51 Analyte 51 Protelos R 51 hypervascular tumors 51 PrandiMet 51 differentially expressed proteins 51 TLR antagonist 51 ColonSentry TM 51 HuMax TF 51 carotid IMT 51 NMIBC 51 NSTE ACS 51 immunohistochemistry IHC 51 Ontak 51 eIF 4E 51 miRview ™ meso 51 sentinel lymph node biopsy 51 renal tumors 51 cystatin 51 PREVU * LT 51 NHAMCS 51 ALA PDT 51 progesterone receptor PR 51 bowel capsule endoscopy 51 Skin sterol 51 Liver Fibrosis 51 nonclinical studies 51 SANVAR 51 imatinib Gleevec 51 Diabetic Foot Ulcer 51 PSADT 51 Mantle Cell Lymphoma 51 Ultrasound imaging 51 Sentinel node biopsy 51 delipidation 51 ELISA kit 51 miRview TM meso 51 anticancer therapies 51 xenograft models 51 sCJD 51 Multivariate analysis 51 electron beam computed tomography 51 NEDD9 51 Patient Registry 51 gene expression profiles 51 VitiGam 51 IRX 2 51 multivariate logistic regression 51 ImmunoCAP ® 51 miRNA expression patterns 51 non squamous NSCLC 51 murine model 51 exploratory endpoints 51 systemic immunosuppressive drugs 51 tanespimycin 51 adenoma detection 51 Onrigin 51 aspirin clopidogrel 51 qualitative serum 51 Lucrin 51 MYOBLOC 51 antiangiogenic activity 51 Hormonal therapy 51 BioZ ICG 51 Trastuzumab DM1 51 radiation chemoradiation 51 conventional cytology 51 ThinPrep Pap Test 51 HuMax CD#b 51 cervical cytology 51 ALTROPANE 51 Mutational 51 ranibizumab Lucentis 51 pretest probability 51 SNP Array #.# 51 HuMax TAC 51 MAGE A3 51 lipid lowering agents 51 autoimmune pancreatitis 51 endoscopic ultrasound EUS 51 TargetScan 51 Intact Digest 51 LT NS# 51 ganetespib 51 dobutamine stress 51 immunotherapeutic approaches 51 Vidaza azacitidine 51 observational cohort study 51 unresectable tumors 51 Li Fraumeni 51 Enzastaurin 51 Prostate specific antigen 51 platelet function 51 HCV antibody 51 HLA DQ2 51 cardiac perfusion 51 SurroMed 51 antihormonal 51 Immunohistochemical staining 51 antioxidant supplementation 51 Rheos System 51 clinically validated 51 Lenalidomide 51 GenPath 51 palliative radiotherapy 51 renoprotective 51 raloxifene Evista 51 microarray experiments 51 pravastatin Pravachol 51 atherosclerosis regression 51 Bayer HealthCare Onyx Pharmaceuticals 51 LightTouch 51 Oxford Immunotec 51 Prospective Randomized 51 metastatic colorectal 51 squamous 51 ResponseDX ™ 51 diabetes mellitus DM 51 multiple logistic regression 51 prospective multicentre 51 ACCORD Lipid 51 Aplidin 51 ASCUS 51 ProFlu + 51 HAAH